Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases

L. Dziggel, B. Segedin, N. H. Podvrsnik, I. Oblak, S. E. Schild, D. Rades

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases. Methods: The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9-18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score. Results: In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9-10 points (group A), 24 % for those with a score of 11-13 points (group B), 51 % for those with a score of 14-16 points (group C), and 82 % for those with scores of 17-18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference. Conclusion: In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalStrahlentherapie und Onkologie
Volume189
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Radiotherapy
Neoplasm Metastasis
Survival Rate
Survival
Brain
Validation Studies
Brain Neoplasms
Research Design
Therapeutics

Keywords

  • Brain metastases
  • Score
  • Survival
  • Validation
  • Whole-brain radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. / Dziggel, L.; Segedin, B.; Podvrsnik, N. H.; Oblak, I.; Schild, S. E.; Rades, D.

In: Strahlentherapie und Onkologie, Vol. 189, No. 5, 05.2013, p. 364-366.

Research output: Contribution to journalArticle

Dziggel, L. ; Segedin, B. ; Podvrsnik, N. H. ; Oblak, I. ; Schild, S. E. ; Rades, D. / Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. In: Strahlentherapie und Onkologie. 2013 ; Vol. 189, No. 5. pp. 364-366.
@article{048387d9bf52403eb02f776703413e60,
title = "Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases",
abstract = "Background: This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases. Methods: The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in {\%}) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9-18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score. Results: In the present validation study, the 6-month survival rates were 8 {\%} for patients with a score of 9-10 points (group A), 24 {\%} for those with a score of 11-13 points (group B), 51 {\%} for those with a score of 14-16 points (group C), and 82 {\%} for those with scores of 17-18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 {\%}, 15 {\%}, 43 {\%}, and 76 {\%}, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference. Conclusion: In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.",
keywords = "Brain metastases, Score, Survival, Validation, Whole-brain radiotherapy",
author = "L. Dziggel and B. Segedin and Podvrsnik, {N. H.} and I. Oblak and Schild, {S. E.} and D. Rades",
year = "2013",
month = "5",
doi = "10.1007/s00066-013-0308-3",
language = "English (US)",
volume = "189",
pages = "364--366",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "5",

}

TY - JOUR

T1 - Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases

AU - Dziggel, L.

AU - Segedin, B.

AU - Podvrsnik, N. H.

AU - Oblak, I.

AU - Schild, S. E.

AU - Rades, D.

PY - 2013/5

Y1 - 2013/5

N2 - Background: This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases. Methods: The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9-18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score. Results: In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9-10 points (group A), 24 % for those with a score of 11-13 points (group B), 51 % for those with a score of 14-16 points (group C), and 82 % for those with scores of 17-18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference. Conclusion: In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.

AB - Background: This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases. Methods: The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9-18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score. Results: In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9-10 points (group A), 24 % for those with a score of 11-13 points (group B), 51 % for those with a score of 14-16 points (group C), and 82 % for those with scores of 17-18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference. Conclusion: In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.

KW - Brain metastases

KW - Score

KW - Survival

KW - Validation

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84877822015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877822015&partnerID=8YFLogxK

U2 - 10.1007/s00066-013-0308-3

DO - 10.1007/s00066-013-0308-3

M3 - Article

C2 - 23519358

AN - SCOPUS:84877822015

VL - 189

SP - 364

EP - 366

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 5

ER -